Gerresheimer's Two-Front Battle: Audit Integrity and Divestiture Timing

Gerresheimer races to secure a clean 2025 audit opinion by June and sell US unit Centor amid regulatory probes. Creditor waivers expire September; stock down 46% in 12 months.

Gerresheimer enters a pivotal summer with two critical balls in the air: a clean audit opinion for its 2025 financials and the sale of its US subsidiary Centor. The packaging specialist is racing to satisfy regulators, creditors, and investors simultaneously — and the outcome could determine whether the stock recovers or slides further.

APAS Takes Aim at KPMG Over Disputed Audit

The Abschlussprüferaufsichtsstelle (APAS) has opened a professional conduct case against auditor KPMG, alleging the firm issued an unqualified opinion on the 2024 annual accounts despite suspected misstatements of roughly €35 million in revenue bookings. KPMG had taken over the audit mandate from Deloitte only in 2024. The probe runs parallel to an ongoing investigation by financial regulator BaFin, which is also scrutinising leasing liability reporting and potential impairments in the Advanced Technologies segment.

This regulatory pressure compounds the existing crisis: Gerresheimer has been unable to publish a certified 2025 annual report for months. The company now targets June for delivering that audit opinion. If successful, attention will shift immediately to the half-year report due in July, which must demonstrate that operations — and the planned sale of US unit Centor — have remained stable through the turmoil.

A Creditor Lifeline With a September Expiry

The company’s lenders have been patient so far. Holders of promissory notes worth some €870 million agreed to extend key covenant waivers until September, buying management time to finalise both the audit and the Centor divestiture. The breathing room is crucial: any further delays or fresh corrections could turn that September deadline into a genuine liquidity threat.

The Centor sale, advised by Morgan Stanley, has attracted strong interest. More than ten bidders are currently reviewing a potential acquisition, and the target remains closing the transaction within the current year. Proceeds are earmarked for debt reduction, a pressing need given the balance sheet strain.

Market Access Stays Blocked Without Certified Accounts

The missing audit opinion is no technicality. Many institutional investors and index-tracking funds are barred by internal compliance rules from holding Gerresheimer shares until a certified financial statement is available. The stock’s expulsion from the SDAX in April — a direct consequence of missed publication deadlines — has already eliminated passive capital inflows.

At €24.94, the share price trades just below its 200-day moving average of €25.46. The year-to-date decline stands at roughly 10%, extending a 12-month drop of more than 46%. Short sellers have slightly reduced their positions recently, but any sustained recovery hinges on a clean audit.

Analyst Divergence Reflects Binary Outcome

The range of analyst targets is unusually wide. JPMorgan rates the stock overweight with a €46.00 target, while UBS recommends sell at €12.90. The consensus target of roughly €23.66 sits below the current market price, implying cautious expectations.

That gap encapsulates two sharply diverging scenarios. A clean June audit could trigger a wave of short covering and renewed buying from institutional sideliners. Conversely, further accounting revisions or delays would bring the September creditor deadline into sharp focus, forcing management into a far more constrained restructuring. The next few weeks will tilt the balance one way or the other.